The Organoid As Reliable Cancer Modeling in Personalized Medicine, Does Applicable in Precision Medicine of Head and Neck Squamous Cell Carcinoma?

Overview

Journal Pharmacogenomics J

Specialties Genetics
Molecular Biology
Pharmacology

Date 2022 Nov 8

PMID 36347937

Authors

Alieh Farshbaf

Malihe Lotfi

Reza Zare

Nooshin Mohtasham

Affiliations

Soon will be listed here.

Abstract

Head and neck squamous cell carcinomas (HNSCCs) are introduced as the sixth most common cancer in the world. Detection of predictive biomarkers improve early diagnosis and prognosis. Recent cancer researches provide a new avenue for organoids, known as "mini-organs" in a dish, such as patient-derived organoids (PDOs), for cancer modeling. HNSCC burden, heterogeneity, mutations, and organoid give opportunities for the evaluation of drug sensitivity/resistance response according to the unique genetic profile signature. The Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR) nucleases, as an efficient genome engineering technology, can be used for genetic manipulation in three-dimensional (3D) organoids for cancer modeling by targeting oncogenes/tumor suppressor genes. Moreover, single-cell analysis of circulating tumor cells (CTCs) improved understanding of molecular angiogenesis, distance metastasis, and drug screening without the need for tissue biopsy. Organoids allow us to investigate the biopathogenesis of cancer, tumor cell behavior, and drug screening in a living biobank according to the specific genetic profile of patients.

Citing Articles

Correlation between clinicopathological indices and expression of cluster of differentiation 24 and cluster of differentiation 44 biomarkers in oral epithelial dysplasia and oral squamous cell carcinoma patients: A follow-up study.

Ghazi N, Saghravanian N, Anvari K, Mirhashemi M, Erfanian M Dent Res J (Isfahan). 2024; 21:50.

PMID: 39376260 PMC: 11457982.

Does circulating tumor DNA apply as a reliable biomarker for the diagnosis and prognosis of head and neck squamous cell carcinoma?.

Ghiyasimoghaddam N, Shayan N, Mirkatuli H, Baghbani M, Ameli N, Ashari Z Discov Oncol. 2024; 15(1):427.

PMID: 39259454 PMC: 11390992. DOI: 10.1007/s12672-024-01308-2.

The potential of hydrogel-free tumoroids in head and neck squamous cell carcinoma.

Wong M, Vasani S, Breik O, Zhang X, Kenny L, Punyadeera C Cancer Med. 2024; 13(16):e70129.

PMID: 39169896 PMC: 11339536. DOI: 10.1002/cam4.70129.

Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy.

Chehelgerdi M, Dehkordi F, Chehelgerdi M, Kabiri H, Salehian-Dehkordi H, Abdolvand M Mol Cancer. 2023; 22(1):189.

PMID: 38017433 PMC: 10683363. DOI: 10.1186/s12943-023-01873-0.

References

Johnson D, Burtness B, Leemans C, Lui V, Bauman J, Grandis J . Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020; 6(1):92. PMC: 7944998. DOI: 10.1038/s41572-020-00224-3. View

Tuna M, Amos C, Mills G . Genome-Wide Analysis of Head and Neck Squamous Cell Carcinomas Reveals HPV, TP53, Smoking and Alcohol-Related Allele-Based Acquired Uniparental Disomy Genomic Alterations. Neoplasia. 2019; 21(2):197-205. PMC: 6321975. DOI: 10.1016/j.neo.2018.12.002. View

Zhou C, Parsons J . The radiobiology of HPV-positive and HPV-negative head and neck squamous cell carcinoma. Expert Rev Mol Med. 2020; 22:e3. PMC: 7754878. DOI: 10.1017/erm.2020.4. View

Wang J, Chen X, Tian Y, Zhu G, Qin Y, Chen X . Six-gene signature for predicting survival in patients with head and neck squamous cell carcinoma. Aging (Albany NY). 2020; 12(1):767-783. PMC: 6977678. DOI: 10.18632/aging.102655. View

Li Y, Tang P, Cai S, Peng J, Hua G . Organoid based personalized medicine: from bench to bedside. Cell Regen. 2020; 9(1):21. PMC: 7603915. DOI: 10.1186/s13619-020-00059-z. View

Yoshida G . Applications of patient-derived tumor xenograft models and tumor organoids. J Hematol Oncol. 2020; 13(1):4. PMC: 6947974. DOI: 10.1186/s13045-019-0829-z. View

Zhao H, Jiang E, Shang Z . 3D Co-culture of Cancer-Associated Fibroblast with Oral Cancer Organoids. J Dent Res. 2020; 100(2):201-208. DOI: 10.1177/0022034520956614. View

Karakasheva T, Kijima T, Shimonosono M, Maekawa H, Sahu V, Gabre J . Generation and Characterization of Patient-Derived Head and Neck, Oral, and Esophageal Cancer Organoids. Curr Protoc Stem Cell Biol. 2020; 53(1):e109. PMC: 7350550. DOI: 10.1002/cpsc.109. View

Neal J, Li X, Zhu J, Giangarra V, Grzeskowiak C, Ju J . Organoid Modeling of the Tumor Immune Microenvironment. Cell. 2018; 175(7):1972-1988.e16. PMC: 6656687. DOI: 10.1016/j.cell.2018.11.021. View

10.

Almangush A, Leivo I, Makitie A . Overall assessment of tumor-infiltrating lymphocytes in head and neck squamous cell carcinoma: time to take notice. Acta Otolaryngol. 2020; 140(3):246-248. DOI: 10.1080/00016489.2020.1720284. View

11.

Kontomanolis E, Koutras A, Syllaios A, Schizas D, Mastoraki A, Garmpis N . Role of Oncogenes and Tumor-suppressor Genes in Carcinogenesis: A Review. Anticancer Res. 2020; 40(11):6009-6015. DOI: 10.21873/anticanres.14622. View

12.

Chandrashekar P, Ahmadinejad N, Wang J, Sekulic A, Egan J, Asmann Y . Somatic selection distinguishes oncogenes and tumor suppressor genes. Bioinformatics. 2020; 36(6):1712-1717. PMC: 7703750. DOI: 10.1093/bioinformatics/btz851. View

13.

Xia X, Li F, He J, Aji R, Gao D . Organoid technology in cancer precision medicine. Cancer Lett. 2019; 457:20-27. DOI: 10.1016/j.canlet.2019.04.039. View

14.

Yuki K, Cheng N, Nakano M, Kuo C . Organoid Models of Tumor Immunology. Trends Immunol. 2020; 41(8):652-664. PMC: 7416500. DOI: 10.1016/j.it.2020.06.010. View

15.

Facompre N, Rajagopalan P, Sahu V, Pearson A, Montone K, James C . Identifying predictors of HPV-related head and neck squamous cell carcinoma progression and survival through patient-derived models. Int J Cancer. 2020; 147(11):3236-3249. PMC: 7554059. DOI: 10.1002/ijc.33125. View

16.

Kretzschmar K . Cancer research using organoid technology. J Mol Med (Berl). 2020; 99(4):501-515. PMC: 8026469. DOI: 10.1007/s00109-020-01990-z. View

17.

Tanaka N, Osman A, Takahashi Y, Lindemann A, Patel A, Zhao M . Head and neck cancer organoids established by modification of the CTOS method can be used to predict in vivo drug sensitivity. Oral Oncol. 2018; 87:49-57. PMC: 6294331. DOI: 10.1016/j.oraloncology.2018.10.018. View

18.

Kijima T, Nakagawa H, Shimonosono M, Chandramouleeswaran P, Hara T, Sahu V . Three-Dimensional Organoids Reveal Therapy Resistance of Esophageal and Oropharyngeal Squamous Cell Carcinoma Cells. Cell Mol Gastroenterol Hepatol. 2018; 7(1):73-91. PMC: 6260338. DOI: 10.1016/j.jcmgh.2018.09.003. View

19.

Mery B, Rancoule C, Guy J, Espenel S, Wozny A, Battiston-Montagne P . Preclinical models in HNSCC: A comprehensive review. Oral Oncol. 2017; 65:51-56. DOI: 10.1016/j.oraloncology.2016.12.010. View

20.

Peria M, Donnadieu J, Racz C, Ikoli J, Galmiche A, Chauffert B . Evaluation of individual sensitivity of head and neck squamous cell carcinoma to cetuximab by short-term culture of tumor slices. Head Neck. 2015; 38 Suppl 1:E911-5. DOI: 10.1002/hed.24126. View